CA3159771A1 - Controlled-delivery cromakalim prodrugs - Google Patents
Controlled-delivery cromakalim prodrugs Download PDFInfo
- Publication number
- CA3159771A1 CA3159771A1 CA3159771A CA3159771A CA3159771A1 CA 3159771 A1 CA3159771 A1 CA 3159771A1 CA 3159771 A CA3159771 A CA 3159771A CA 3159771 A CA3159771 A CA 3159771A CA 3159771 A1 CA3159771 A1 CA 3159771A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- disorder
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/09—Diamines
- C07C211/10—Diaminoethanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962947342P | 2019-12-12 | 2019-12-12 | |
| US62/947,342 | 2019-12-12 | ||
| PCT/US2020/064629 WO2021119503A1 (en) | 2019-12-12 | 2020-12-11 | Controlled-delivery cromakalim prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3159771A1 true CA3159771A1 (en) | 2021-06-17 |
Family
ID=76330627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3159771A Pending CA3159771A1 (en) | 2019-12-12 | 2020-12-11 | Controlled-delivery cromakalim prodrugs |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12454539B2 (https=) |
| EP (1) | EP4072543A4 (https=) |
| JP (1) | JP7636742B2 (https=) |
| CN (1) | CN115443132A (https=) |
| AU (1) | AU2020403144A1 (https=) |
| CA (1) | CA3159771A1 (https=) |
| WO (1) | WO2021119503A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021215932A1 (en) * | 2020-02-07 | 2022-09-15 | Mayo Foundation For Medical Education And Research | Improved methods and compositions for cromakalim prodrug therapy |
| EP4384162A4 (en) * | 2021-08-12 | 2025-06-04 | Qlaris Bio, Inc. | Compositions and methods for extended-release bromo-kallim therapy |
| IL320428A (en) | 2022-11-04 | 2025-06-01 | Qlaris Bio Inc | Topical ophthalmic administration of cromolyns |
| CN119970613B (zh) * | 2025-02-10 | 2026-03-03 | 中国人民解放军总医院 | 一种埃他卡林微针及其制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2986573A (en) | 1961-01-18 | 1961-05-30 | Schering Corp | Method for the treatment of hypertension |
| US3361816A (en) | 1961-02-20 | 1968-01-02 | Schering Corp | Novel therapeutic compounds and processes for their manufacture |
| US3251837A (en) | 1962-09-14 | 1966-05-17 | Pfizer & Co C | Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides |
| US4200640A (en) | 1976-04-02 | 1980-04-29 | Chugai Seiyaku Kabushiki Kaisha | Nitric ester of N-(2-hydroxyethyl)nicotinamide and pharmaceutical use |
| IE52935B1 (en) | 1981-04-15 | 1988-04-13 | Leo Pharm Prod Ltd | Pharmaceutical preparation |
| GB8308062D0 (en) | 1983-03-24 | 1983-05-05 | Beecham Group Plc | Active compounds |
| US4616012A (en) | 1983-11-25 | 1986-10-07 | Schering Corporation | Carboxyalkyl dipeptides as antiglaucoma agents |
| US4634698A (en) | 1984-09-24 | 1987-01-06 | Schering Corporation | Antiglaucoma agents |
| GB8730051D0 (en) | 1987-12-23 | 1988-02-03 | Beecham Group Plc | Novel compounds |
| AU628331B2 (en) | 1988-05-06 | 1992-09-17 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Chroman derivatives |
| WO1989010757A1 (en) | 1988-05-10 | 1989-11-16 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis | New ophthalmic preparation for treating glaucoma |
| GB8822743D0 (en) | 1988-09-28 | 1988-11-02 | Beecham Group Plc | Novel compounds |
| GB8927980D0 (en) | 1989-12-11 | 1990-02-14 | Beecham Group Plc | Pharmaceuticals |
| US5565560A (en) | 1991-05-13 | 1996-10-15 | Merck & Co., Inc. | O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
| US5328830A (en) | 1992-09-08 | 1994-07-12 | Miles Inc. | Potassium channel modulators |
| US5965620A (en) | 1993-07-23 | 1999-10-12 | Vide Pharmaceuticals | Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure |
| US6242443B1 (en) | 1996-06-21 | 2001-06-05 | Novo Nordisk Ais | 1,2,4-benzothiadiazine derivatives, their preparation and use |
| FR2767692B1 (fr) | 1997-09-01 | 2000-03-03 | Oreal | Utilisation d'une substance agoniste d'un recepteur associe a un canal chlore ou potassique dans le traitement des peaux sensibles |
| AU754965B2 (en) | 1997-12-31 | 2002-11-28 | University Of Kansas, The | Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof |
| US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
| US7186707B2 (en) | 2002-04-01 | 2007-03-06 | University Of Florida | Prodrugs for use as ophthalmic agents |
| CN101327325A (zh) | 2002-07-30 | 2008-12-24 | 奥默罗斯公司 | 眼科冲洗液及方法 |
| FR2852245B1 (fr) | 2003-03-11 | 2006-08-11 | Utilisation du diazoxide dans le traitement de l'ischemie retinienne | |
| ES2342090T3 (es) | 2004-08-25 | 2010-07-01 | Essentialis, Inc. | Formulaciones farmaceuticas de agentes de apertura de canales de potasio dependientes de atp y usos de los mismos. |
| GB0702972D0 (en) * | 2007-02-15 | 2007-03-28 | Cambridge Entpr Ltd | Induction of autography |
| JP5681723B2 (ja) | 2009-11-20 | 2015-03-11 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用 |
| JP2011136923A (ja) | 2009-12-28 | 2011-07-14 | Lion Corp | ソフトコンタクトレンズ用点眼剤 |
| WO2013130411A1 (en) | 2012-02-27 | 2013-09-06 | Essentialis, Inc. | Salts of potassium atp channel openers and uses thereof |
| DK2838533T3 (da) | 2012-04-16 | 2017-11-27 | Univ Case Western Reserve | Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet |
| US10981951B2 (en) * | 2014-01-31 | 2021-04-20 | Mayo Foundation For Medical Education And Research | Therapeutics for the treatment of glaucoma |
| AU2015296640B2 (en) * | 2014-07-30 | 2020-05-21 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| WO2018047175A1 (en) | 2016-09-08 | 2018-03-15 | Regenera Pharma Ltd. | Compositions comprising triterpenoids and uses thereof for treating optic neuropathy |
| AU2021215932A1 (en) | 2020-02-07 | 2022-09-15 | Mayo Foundation For Medical Education And Research | Improved methods and compositions for cromakalim prodrug therapy |
-
2020
- 2020-12-11 CA CA3159771A patent/CA3159771A1/en active Pending
- 2020-12-11 JP JP2022535602A patent/JP7636742B2/ja active Active
- 2020-12-11 WO PCT/US2020/064629 patent/WO2021119503A1/en not_active Ceased
- 2020-12-11 EP EP20897717.3A patent/EP4072543A4/en active Pending
- 2020-12-11 AU AU2020403144A patent/AU2020403144A1/en active Pending
- 2020-12-11 CN CN202080095951.5A patent/CN115443132A/zh active Pending
-
2022
- 2022-06-09 US US17/836,871 patent/US12454539B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7636742B2 (ja) | 2025-02-27 |
| US12454539B2 (en) | 2025-10-28 |
| EP4072543A4 (en) | 2024-02-07 |
| CN115443132A (zh) | 2022-12-06 |
| US20220324890A1 (en) | 2022-10-13 |
| WO2021119503A1 (en) | 2021-06-17 |
| JP2023506776A (ja) | 2023-02-20 |
| EP4072543A1 (en) | 2022-10-19 |
| AU2020403144A1 (en) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12454539B2 (en) | Controlled-delivery cromakalim prodrugs | |
| CN109528721B (zh) | 联合治疗 | |
| US20220387457A1 (en) | Methods and compositions for cromakalim prodrug therapy | |
| EA016227B1 (ru) | Способ лечения офтальмологических неоваскулярных расстройств | |
| US20200308162A1 (en) | Drugs and compositions for ocular delivery | |
| AU2023201678B2 (en) | Methods for the use of 5'-adenosine diphosphate ribose (ADPR) | |
| CN107823202B (zh) | 睑板腺功能障碍的治疗剂 | |
| CN113661170B (zh) | 地塞米松二聚体的结晶形式及其用途 | |
| JP2024532015A (ja) | 徐放性クロマカリム療法用の組成物及び方法 | |
| JP2012006918A (ja) | イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤 | |
| ES2717481T3 (es) | Engrosamiento corneal central reducido mediante el uso de profármacos de ésteres hidrófilos de beta-clorociclopentanos | |
| US20250170143A1 (en) | Methods of treating ocular fibrotic pathologies | |
| CN101389336A (zh) | 用于抑制补体激活的羟胺类和衍生物 | |
| HK40004468A (en) | Combination therapy | |
| HK1263210B (en) | Medical use of 5'-adenosine diphosphate ribose (adpr) | |
| EP1996195A2 (en) | Hydroxylamines and derivatives for the inhibition of complement activation | |
| HK1217445B (en) | Therapeutic agent for meibomian dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241007 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241112 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241112 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241112 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241206 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241206 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241206 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250103 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250103 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250414 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250414 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250523 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251231 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260226 |